PE20150084A1 - Metodos para producir clorhidrato de anamorelina que tiene contenido controlado de cloruro - Google Patents

Metodos para producir clorhidrato de anamorelina que tiene contenido controlado de cloruro

Info

Publication number
PE20150084A1
PE20150084A1 PE2014001624A PE2014001624A PE20150084A1 PE 20150084 A1 PE20150084 A1 PE 20150084A1 PE 2014001624 A PE2014001624 A PE 2014001624A PE 2014001624 A PE2014001624 A PE 2014001624A PE 20150084 A1 PE20150084 A1 PE 20150084A1
Authority
PE
Peru
Prior art keywords
chloride content
methods
controlled chloride
anamorelin hydrochloride
weight
Prior art date
Application number
PE2014001624A
Other languages
English (en)
Inventor
Shin-Itsu Kuwabe
Takehiko Yanagimachi
Hideyuki Yoshiyama
Seemon Pines
Groot Eleanor De
Rubio Silvina Garcia
Peter Manini
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48225135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150084(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of PE20150084A1 publication Critical patent/PE20150084A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

REFERIDA AL MONOCLORHIDRATO DE ANAMORELINA AISLADO, EN ESTADO AMORFO, QUE TIENE UN CONTENIDO DE CLORURO EN UN RANGO DE ENTRE 5,8% A 6,2% POR PESO Y COMPRENDE MENOS DE 0,5% POR PESO DE IMPUREZAS TALES COMO CONTAMINANTES, PRODUCTOS DE DEGRADACION Y SOLVENTES RESIDUALES. EL SOLVENTE RESIDUAL ES ACETATO DE BUTILO, ACETATO DE ISOPROPILO, ACETATO DE METILO, METILETILCETONA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA
PE2014001624A 2012-04-20 2013-04-18 Metodos para producir clorhidrato de anamorelina que tiene contenido controlado de cloruro PE20150084A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261636108P 2012-04-20 2012-04-20

Publications (1)

Publication Number Publication Date
PE20150084A1 true PE20150084A1 (es) 2015-01-23

Family

ID=48225135

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001624A PE20150084A1 (es) 2012-04-20 2013-04-18 Metodos para producir clorhidrato de anamorelina que tiene contenido controlado de cloruro

Country Status (47)

Country Link
US (8) US20140018391A1 (es)
EP (3) EP3290410B1 (es)
JP (3) JP6109925B2 (es)
KR (2) KR101972998B1 (es)
CN (3) CN110041304A (es)
AP (1) AP2014008013A0 (es)
AR (1) AR090725A1 (es)
AU (1) AU2013249197B2 (es)
BR (1) BR112014025972A8 (es)
CA (2) CA3031652C (es)
CL (1) CL2014002817A1 (es)
CO (1) CO7131356A2 (es)
CR (1) CR20140530A (es)
CY (1) CY1120276T1 (es)
DK (2) DK2838892T3 (es)
DO (1) DOP2014000235A (es)
EA (1) EA031581B1 (es)
EC (1) ECSP14027739A (es)
ES (2) ES2658862T3 (es)
GE (1) GEP20186902B (es)
HK (2) HK1202863A1 (es)
HR (1) HRP20180316T1 (es)
HU (2) HUE035697T2 (es)
IL (1) IL235064B (es)
JO (1) JO3353B1 (es)
LT (1) LT2838892T (es)
MA (1) MA37524B1 (es)
MD (1) MD4615C1 (es)
ME (1) ME02966B (es)
MX (1) MX354793B (es)
MY (1) MY170068A (es)
NI (1) NI201400124A (es)
NO (1) NO2877697T3 (es)
NZ (1) NZ700833A (es)
PE (1) PE20150084A1 (es)
PH (1) PH12014502351B1 (es)
PL (2) PL3290410T3 (es)
PT (2) PT2838892T (es)
RS (1) RS56869B1 (es)
SG (2) SG11201406478XA (es)
SI (2) SI2838892T1 (es)
TN (1) TN2014000421A1 (es)
TW (2) TWI589572B (es)
UA (1) UA116207C2 (es)
UY (1) UY34753A (es)
WO (1) WO2013158874A1 (es)
ZA (1) ZA201408508B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
CN113577074A (zh) * 2014-09-04 2021-11-02 赫尔森保健股份公司 基于阿拉莫林的药物治疗
KR20180086300A (ko) 2015-07-24 2018-07-30 뉴링크 제네틱스 코퍼레이션 1-메틸-d-트립토판의 염 및 프로드러그
CN108239141A (zh) * 2016-12-23 2018-07-03 江苏先声药业有限公司 一种阿拉莫林的制备方法
KR20220054244A (ko) 2019-08-30 2022-05-02 헬신 헬스케어 에스아 개선된 안정성을 갖는 아나모렐린 정제의 제조 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
CN1882526A (zh) * 2003-09-26 2006-12-20 兰贝克赛实验室有限公司 制备伏格列波糖的方法
EP2298760B1 (en) 2004-06-29 2015-08-05 Helsinn Healthcare S.A. Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
MX2009008561A (es) * 2007-02-13 2010-01-15 Helsinn Therapeutics Us Inc Metodo para tratar trastornos proliferativos celulares utilizando secretagogos.
UA105657C2 (uk) * 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي

Also Published As

Publication number Publication date
US9981002B2 (en) 2018-05-29
UY34753A (es) 2013-11-29
WO2013158874A1 (en) 2013-10-24
CR20140530A (es) 2015-03-25
US20190231843A1 (en) 2019-08-01
SG11201406478XA (en) 2014-11-27
JP6616853B2 (ja) 2019-12-04
EP2838892B1 (en) 2017-12-06
AU2013249197B2 (en) 2017-04-06
US20160229889A1 (en) 2016-08-11
KR101972998B1 (ko) 2019-04-29
AU2013249197A1 (en) 2014-10-30
MX2014012178A (es) 2015-08-05
SI3290410T1 (sl) 2020-11-30
NI201400124A (es) 2015-09-21
TWI589572B (zh) 2017-07-01
JO3353B1 (ar) 2019-03-13
HK1202863A1 (en) 2015-10-09
CA2869893C (en) 2019-03-05
BR112014025972A8 (pt) 2021-06-22
US10905737B2 (en) 2021-02-02
CN110041304A (zh) 2019-07-23
LT2838892T (lt) 2018-03-12
CY1120276T1 (el) 2019-07-10
EA201401151A1 (ru) 2015-06-30
GEP20186902B (en) 2018-10-25
JP2018076375A (ja) 2018-05-17
MA37524A1 (fr) 2016-06-30
KR20150013115A (ko) 2015-02-04
CN103857669A (zh) 2014-06-11
PT2838892T (pt) 2018-02-28
DK3517532T3 (da) 2022-01-03
MD4615B1 (ro) 2019-01-31
ZA201408508B (en) 2020-01-29
PH12014502351A1 (en) 2015-01-12
JP6109925B2 (ja) 2017-04-05
ME02966B (me) 2018-07-20
SI2838892T1 (en) 2018-05-31
IL235064A0 (en) 2014-12-31
ECSP14027739A (es) 2015-12-31
US20140018391A1 (en) 2014-01-16
US20160235804A1 (en) 2016-08-18
EP2838892A1 (en) 2015-02-25
JP2015514779A (ja) 2015-05-21
US10300105B2 (en) 2019-05-28
KR102141323B1 (ko) 2020-08-05
MA37524B1 (fr) 2017-04-28
EA031581B1 (ru) 2019-01-31
TWI677494B (zh) 2019-11-21
ES2658862T3 (es) 2018-03-12
MY170068A (en) 2019-07-03
UA116207C2 (uk) 2018-02-26
BR112014025972A2 (pt) 2017-06-27
EP3517532A1 (en) 2019-07-31
MX354793B (es) 2018-03-21
CN103857669B (zh) 2019-06-28
CN110041398A (zh) 2019-07-23
US9956261B2 (en) 2018-05-01
HK1248694A1 (zh) 2018-10-19
PL2838892T3 (pl) 2018-05-30
HUE050865T2 (hu) 2021-01-28
US9872883B2 (en) 2018-01-23
JP6284665B2 (ja) 2018-02-28
HRP20180316T1 (hr) 2018-04-06
PT3517532T (pt) 2021-11-08
DK2838892T3 (en) 2018-03-12
CA2869893A1 (en) 2013-10-24
MD20140122A2 (ro) 2015-05-31
TW201348224A (zh) 2013-12-01
US9403867B2 (en) 2016-08-02
US20190000914A1 (en) 2019-01-03
US20150072934A1 (en) 2015-03-12
EP3290410A1 (en) 2018-03-07
SG10201608488RA (en) 2016-12-29
RS56869B1 (sr) 2018-04-30
MD4615C1 (ro) 2019-08-31
PH12014502351B1 (en) 2015-01-12
EP3517532B1 (en) 2021-10-13
CO7131356A2 (es) 2014-12-01
NZ700833A (en) 2016-01-29
DOP2014000235A (es) 2015-01-31
US20200276259A1 (en) 2020-09-03
CL2014002817A1 (es) 2015-08-14
TW201722928A (zh) 2017-07-01
CA3031652A1 (en) 2013-10-24
KR20190044697A (ko) 2019-04-30
TN2014000421A1 (en) 2016-03-30
HUE035697T2 (en) 2018-05-28
US20160237115A1 (en) 2016-08-18
JP2017101082A (ja) 2017-06-08
IL235064B (en) 2019-09-26
PL3290410T3 (pl) 2021-01-11
US10576122B2 (en) 2020-03-03
CA3031652C (en) 2020-10-27
AR090725A1 (es) 2014-12-03
ES2820354T3 (es) 2021-04-20
AP2014008013A0 (en) 2014-10-31
EP3290410B1 (en) 2020-07-01
NO2877697T3 (es) 2018-10-13

Similar Documents

Publication Publication Date Title
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
UY34917A (es) Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación
BR112014032990A2 (pt) seringa
GT201400111A (es) Triazolopiridinas sustituidas
EA201590951A1 (ru) Дигидропиразольные модуляторы gpr40
IN2013CN09704A (es)
MX348654B (es) Composicion farmaceutica con biodisponibilidad mejorada para compuesto hidrofobico de alto punto de fusion.
CL2014000806A1 (es) Compuestos derivados de 1-arilcarbonil-4-oxi-piperidino; composicion farmaceutica que los comprende; uso para la prevencion o el tratamiento de enfermedades neurodegenerativas tales como enfermedad de alzheimer, enfermedad de parkinson, enfermedad de huntington o esclerosis multiple.
PE20150084A1 (es) Metodos para producir clorhidrato de anamorelina que tiene contenido controlado de cloruro
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CU20160169A7 (es) Compuestos y composiciones para inducir condrogénesis
CO6741223A2 (es) Derivados de azetidina útiles para el tratamiento de enfermedades metabólicas e inflamatorias
EA201590949A1 (ru) Дигидропиразольные модуляторы gpr40
EA201590954A1 (ru) Дигидропиразольные модуляторы gpr40
CR20130693A (es) Composición farmacéutica ortalmológica tópica que contiene regorafenib
ES2421956A1 (es) Nueva forma cristalina de sulfato de sitagliptina
BR112015022859A2 (pt) processo para fabricação de mono-hidrato trissódico gadofosveset
EA201600394A1 (ru) Трициклические соединения пиперидина
UY35253A (es) Compuesto farmacéutico para la prevención y el tratamiento de un trastorno o una enfermedad cogniti vos, neurodegenerativos o neuronales
CL2014000509A1 (es) Co-cristales que comprenden ciprodinil y ditianon; proceso para preparar los co-cristales; composicion para la proteccion de cultivos que comprende dichos co-cristales; uso para combatir hobgos fitopatógenos.
CO6831981A2 (es) Productos médicos para uso en enfermedades relacionadas con infecciones microbianas en el tracto aerodigestivo superior
CR20150327A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
CL2012000393A1 (es) Compuestos octasacaridos n-acilados; composicion farmaceutica; intermediarios; utiles en el tratamiento de enfermedades tales como isquemia, angina de pecho, aterosclerosis, entre otras.

Legal Events

Date Code Title Description
FC Refusal